Prof. Daniel Hoyer, PhD, DSc, FBPharmacolS
Prof. Hoyer's research career can be traced from his PhD in Pharmacology (1981), DSc (1986 Strasbourg), post-doctoral work (University of Pennsylvania, Medical School, Pharmacology), via Cardiovascular Research at Sandoz (Basel, 1983) to the CNS division (1989). At Novartis, Hoyer worked on both drug development and basic science projeects, e.g. genomics of depression and schizophrenia (MPRC, Baltimore; Scripps & GNF, La Jolla), peptide receptors and their chemistry (European Consortium). His recent interests were in Epilepsy, Sleep disorders, RNAi and epigenetics.
Prof. Hoyer has published over 300 papers, and is/was member of British and German Pharmacological Societies, European College of Neuropsychopharmacology, Society for Neurosciences, served at the scientific council of Institut Pasteur and on the Council and a Director of the BPS. Prof. Hoyer has served as editor of European Journal of Pharmacology, Neuropharmacology, Current Opinions in Pharmacology, Current Drugs, Drug Discovery Today, Journal of Receptors & Signal Transduction, Pharmacology & Therapy. He is currently a senior editor of Psychopharmacology, Naunyn Schmiedeberg's Archives of Pharmacology, Encyclopedia of Psychopharmacology, British Journal of Pharmacology. Prof. Hoyer chaired the somatostatin and 5-HT receptor subcommittees (NC IUPHAR) and was President of the European Neuropeptide Club and of the International Society for Serotonin Research.
Prof. Hoyer was in the top 10 most cited researchers in Pharmacology, Novartis Leading Scientist (1998), Manfred Zimmerman Award (2003), Professor adjunct at the Molecular and Integrative Neurosciences Department, Scripps Research Institute, La Jolla (2004), Fellow of the British Pharmacological Society (2005); since November 2012, Professor, Chair and Head, Department of Pharmacology, School of Medicine, The University of Melbourne.